While cannabinoids offer a potential alternative for refractory chronic pain, optimal use requires personalized dosing and ...

Algiax Pharmaceuticals, a company committed to developing innovative treatments for chronic neuropathic pain, has released ...

A painkiller developed by Germany's Algiax Pharma has shown efficacy in the treatment of chronic neuropathic pain, another positive development in the search for alternatives to opioids.

The Phase IIa results continue a surge of momentum in a treatment space that last week saw the approval of Vertex’s Journavx ...

Navega Therapeutics, a biotechnology company developing epigenetic gene therapies, today announced the receipt of a $4M ...

Vertex's Journavx got FDA approval for acute pain but faces adoption challenges. Click here to read more about VRTX stock and ...

Algiax Pharmaceuticals, a clinical-stage biotech company focused on developing innovative treatments for chronic neuropathic pain, today announced compelling topline data from its Phase 2a clinical ...

Düsseldorf, Germany Wednesday, February 5, 2025, 18:00 Hrs [IST] ...

I was under the impression that only older adults got shingles,” says Mangini, who was 37 at the time. The rash spread, yet ...

It is important to add pain management to leprosy treatment protocols. This can reduce the challenges that patients face. Read on.

The FDA has approved Journavx, a new non-opioid painkiller designed to treat moderate to severe acute pain. Unlike opioids, ...